de BlackRock Acadia Pharmaceuticals ACAD Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 570 M | Comprar |
22,515,173
+964,252
| +4% | +USD 21.2 M | 0.01% | 1136 |
|
|
2026
Q1 | USD 480 M | Comprar |
21,550,921
+795,469
| +4% | +USD 19 M | 0.01% | 1135 |
|
|
2025
Q4 | USD 554 M | Comprar |
20,755,452
+486,808
| +2% | +USD 11.6 M | 0.01% | 1026 |
|
|
2025
Q3 | USD 433 M | Vender |
20,268,644
-383,772
| -2% | -USD 9.08 M | 0.01% | 1187 |
|
|
2025
Q2 | USD 445 M | Vender |
20,652,416
-714,141
| -3% | -USD 13.3 M | 0.01% | 1129 |
|
|
2025
Q1 | USD 355 M | Comprar |
21,366,557
+8,636,698
| +68% | +USD 157 M | 0.01% | 1240 |
|
|
2024
Q4 | USD 234 M | Vender |
12,729,859
-64,962
| -0.5% | -USD 1.05 M | ﹤0.01% | 1585 |
|
|
2024
Q3 | USD 197 M | Comprar |
12,794,821
+732,608
| +6% | +USD 12.2 M | ﹤0.01% | 1667 |
|
|
2024
Q2 | USD 196 M | Comprar |
12,062,213
+393,473
| +3% | +USD 6.35 M | ﹤0.01% | 1634 |
|
|
2024
Q1 | USD 216 M | Comprar |
11,668,740
+258,257
| +2% | +USD 6.4 M | 0.01% | 1600 |
|
|
2023
Q4 | USD 357 M | Comprar |
11,410,483
+1,381,898
| +14% | +USD 33 M | 0.01% | 1260 |
|
|
2023
Q3 | USD 209 M | Vender |
10,028,585
-10,916
| -0.1% | -USD 296 k | 0.01% | 1510 |
|
|
2023
Q2 | USD 240 M | Comprar |
10,039,501
+170,370
| +2% | +USD 3.79 M | 0.01% | 1454 |
|
|
2023
Q1 | USD 186 M | Vender |
9,869,131
-390,053
| -4% | -USD 7.43 M | 0.01% | 1593 |
|
|
2022
Q4 | USD 163 M | Comprar |
10,259,184
+286,029
| +3% | +USD 4.47 M | 0.01% | 1683 |
|
|
2022
Q3 | USD 163 M | Comprar |
9,973,155
+231,841
| +2% | +USD 3.75 M | 0.01% | 1630 |
|
|
2022
Q2 | USD 137 M | Vender |
9,741,314
-228,709
| -2% | -USD 4.27 M | ﹤0.01% | 1816 |
|
|
2022
Q1 | USD 241 M | Vender |
9,970,023
-90,289
| -0.9% | -USD 2.18 M | 0.01% | 1524 |
|
|
2021
Q4 | USD 235 M | Vender |
10,060,312
-94,639
| -0.9% | -USD 1.9 M | 0.01% | 1613 |
|
|
2021
Q3 | USD 169 M | Comprar |
10,154,951
+15,748
| +0.2% | +USD 304 k | ﹤0.01% | 1848 |
|
|
2021
Q2 | USD 247 M | Comprar |
10,139,203
+2,737,601
| +37% | +USD 61.8 M | 0.01% | 1614 |
|
|
2021
Q1 | USD 191 M | Comprar |
7,401,602
+170,805
| +2% | +USD 7.52 M | 0.01% | 1770 |
|
|
2020
Q4 | USD 387 M | Comprar |
7,230,797
+69,586
| +1% | +USD 3.45 M | 0.01% | 1086 |
|
|
2020
Q3 | USD 295 M | Vender |
7,161,211
-596,635
| -8% | -USD 25.8 M | 0.01% | 1083 |
|
|
2020
Q2 | USD 376 M | Vender |
7,757,846
-2,378,264
| -23% | -USD 114 M | 0.02% | 891 |
|
|
2020
Q1 | USD 428 M | Vender |
10,136,110
-102,785
| -1% | -USD 4.24 M | 0.02% | 692 |
|
|
2019
Q4 | USD 438 M | Comprar |
10,238,895
+709,570
| +7% | +USD 30.9 M | 0.02% | 893 |
|
|
2019
Q3 | USD 343 M | Vender |
9,529,325
-124,239
| -1% | -USD 3.77 M | 0.01% | 1018 |
|
|
2019
Q2 | USD 258 M | Vender |
9,653,564
-1,065,144
| -10% | -USD 27.2 M | 0.01% | 1237 |
|
|
2019
Q1 | USD 288 M | Comprar |
10,718,708
+585,242
| +6% | +USD 13.7 M | 0.01% | 1141 |
|
|
2018
Q4 | USD 164 M | Comprar |
10,133,466
+346,561
| +4% | +USD 6.73 M | 0.01% | 1456 |
|
|
2018
Q3 | USD 203 M | Comprar |
9,786,905
+51,804
| +0.5% | +USD 815 k | 0.01% | 1491 |
|
|
2018
Q2 | USD 149 M | Comprar |
9,735,101
+3,085,874
| +46% | +USD 55 M | 0.01% | 1660 |
|
|
2018
Q1 | USD 149 M | Vender |
6,649,227
-61,470
| -0.9% | -USD 1.7 M | 0.01% | 1567 |
|
|
2017
Q4 | USD 202 M | Comprar |
6,710,697
+321,950
| +5% | +USD 10.3 M | 0.01% | 1367 |
|
|
2017
Q3 | USD 241 M | Comprar |
6,388,747
+798,041
| +14% | +USD 26 M | 0.01% | 1191 |
|
|
2017
Q2 | USD 156 M | Comprar |
5,590,706
+157,497
| +3% | +USD 4.69 M | 0.01% | 1488 |
|
|
2017
Q1 | USD 187 M | Comprar |
5,433,209
+5,334,832
| +5,423% | +USD 188 M | 0.01% | 1349 |
|
|
2016
Q4 | USD 2.84 M | Comprar |
98,377
+84,906
| +630% | +USD 2.25 M | ﹤0.01% | 1093 |
|
|
2016
Q3 | USD 428 k | Comprar |
13,471
+1,094
| +9% | +USD 37.1 k | ﹤0.01% | 1798 |
|
|
2016
Q2 | USD 401 k | Comprar |
12,377
+6,963
| +129% | +USD 233 k | ﹤0.01% | 1758 |
|
|
2016
Q1 | USD 152 k | Comprar |
5,414
+3,153
| +139% | +USD 68.8 k | ﹤0.01% | 1814 |
|
|
2015
Q4 | USD 81 k | Comprar |
2,261
+542
| +32% | +USD 19.1 k | ﹤0.01% | 1836 |
|
|
2015
Q3 | USD 57 k | Vender |
1,719
-337
| -16% | -USD 14 k | ﹤0.01% | 1862 |
|
|
2015
Q2 | USD 86 k | Vender |
2,056
-22
| -1% | -USD 851 | ﹤0.01% | 1835 |
|
|
2015
Q1 | USD 68 k | Mantener |
2,078
| – | – | ﹤0.01% | 1853 |
|
|
2014
Q4 | USD 66 k | Vender |
2,078
-330
| -14% | -USD 9.36 k | ﹤0.01% | 1846 |
|
|
2014
Q3 | USD 60 k | Mantener |
2,408
| – | – | ﹤0.01% | 1847 |
|
|
2014
Q2 | USD 55 k | Vender |
2,408
-103
| -4% | -USD 2.15 k | ﹤0.01% | 1896 |
|
|
2014
Q1 | USD 61 k | Comprar |
2,511
+147
| +6% | +USD 3.72 k | ﹤0.01% | 1829 |
|
|
2013
Q4 | USD 59 k | Mantener |
2,364
| – | – | ﹤0.01% | 1877 |
|
|
2013
Q3 | USD 65 k | Vender |
2,364
-40,877
| -95% | -USD 855 k | ﹤0.01% | 1762 |
|
|
2013
Q2 | USD 784 k | Comprar |
+43,241
| Nuevas | +USD 596 k | ﹤0.01% | 1109 |
|
Otros fondos que tienen ACAD en su cartera
BBA
Posición de BlackRock en ACAD: resumen de T2 2026
BlackRock aumentó su participación en Acadia Pharmaceuticals (ACAD) en 4.5% durante T2 2026, al comprar aproximadamente USD 21.2 M y elevar la posición a 22,515,173 acciones con un valor de USD 570 M. La posición representa 0.01% de la cartera y ocupa el puesto #1136.
BlackRock reportó por primera vez una posición en ACAD en T2 2013 y la ha mantenido durante 53 trimestres desde entonces. Al cierre de T2 2026, 354 fondos que sigue Wall St. Rank mantienen una posición en ACAD.
- Al cierre de T2 2026, BlackRock tenía 22,515,173 acciones de Acadia Pharmaceuticals con un valor de USD 570 M.
- BlackRock compró 964,252 acciones de Acadia Pharmaceuticals en T2 2026, por un monto estimado de USD 21.2 M.
- Acadia Pharmaceuticals representó 0.01% de la cartera de BlackRock en T2 2026 y fue su posición número 1136.
- BlackRock reportó por primera vez una posición en Acadia Pharmaceuticals en T2 2013 y la ha mantenido durante 53 trimestres desde entonces.
- Al cierre de T2 2026, 354 fondos que sigue Wall St. Rank tenían Acadia Pharmaceuticals en cartera.
Según el Informe 13F de BlackRock correspondiente a T2 2026, presentado el 7 ago 2026.